Skip to search formSkip to main contentSkip to account menu

LY 573636

Known as: LY-573636, LY573636 
National Institutes of Health

Related topics

Related topics

1 relation
tasisulam

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Efficient synthesis of carbon-11 labelled acylsulfonamides using [11C]CO carbonylation chemistry.
Herein, a novel method for carbon-11 labeling of acyl sulfonamides by a one-step insertive [11C]CO carbonylative cross-coupling… 
2013
2013
A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma
SummaryBackground Tasisulam sodium (hereafter tasisulam), a novel anticancer agent, is being studied in a broad range of tumors… 
2008
2008
Novel acyl sulfonamide LY573636-sodium: effect on hematopoietic malignant cells.
LY573636-sodium is a promising anti-tumor agent, which causes growth arrest and apoptosis of a variety of human solid tumors in… 
2004
2004
228 A phase I trial of LY573636 in patients with advanced solid tumors
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)